Molecular modeling study of HIV-1 gp120 attachment inhibitors

Abstract

The viral glycoprotein 120 (gp120) is a glycoprotein exposed on viral surface. The gp120 is essential for virus entry into cells as it plays a vital role in seeking out specific cell surface receptors for entry. In this article, we performed docking and three-dimensional quantitative structure activity relationship (3D-QSAR) study on a series of 48 indole glyoxamide derivatives as gp120 inhibitors. Docking study revealed that the inhibitor docked deeply into the gp120 cavity rather than Phe43 of cluster of differentiation 4 (CD4). 3D-QSAR methodologies, comparative molecular field analysis (CoMFA), and comparative molecular similarity indices analysis (CoMSIA) were utilized to rationalize the structural variations with their inhibitory activities. The docked pose of the most potent molecule (43) was used to determine the structures of other molecules. The CoMFA yielded a model with cross-validated correlation coefficient of (q 2) 0.73 and non-cross-validated correlation coefficient of (r 2) 0.89 with optimum number of components (N = 3). The CoMSIA models were obtained with the combination of various parameters. Final model was computed with steric, hydrophobic- and hydrogen-bond acceptor (SHA) parameters with reasonable statistics (q 2 = 0.80, r 2 = 0.94 and N = 5). The predictive power of developed CoMFA and CoMSIA models were assessed by test set (nine molecules). The predictive r pred 2 for CoMFA and CoMSIA model was found to be 0.93 and 0.74, respectively. The generated contour maps were plotted onto the gp120 active site to correlate structural variations with their biological activity in protein environment. Contour map analyses showed the importance of 4-F substitution of indole ring, which made essential electronic interaction with the crucial residue (Trp427). The 3D models could explain nicely the structure–activity relationships of indole glyoxamide analogs. This would give proper guidelines to further enhance the activity of novel inhibitors.